Advanced Hemodynamic Monitoring Study for Surgical Patients

Edwards Lifesciences is conducting an important observational research study called the HemoSphere Alta Clinical Development Study to evaluate advanced monitoring technology for patients undergoing major surgery. This study focuses on patients who experience hemodynamic instability - changes in blood flow and pressure that can occur during complex surgical procedures. The research will help medical professionals better understand how to monitor and support patients' cardiovascular systems during critical operations.

The study will enroll up to 100 adult participants who are scheduled for cardiac or liver transplant surgery lasting more than two hours and require monitoring with a pulmonary artery catheter. Participants will be monitored using the HemoSphere Alta system along with several specialized sensors that provide detailed information about heart function, blood flow, and oxygen delivery to vital organs. This comprehensive monitoring approach allows doctors to gather precise data about how the body responds to surgical stress and anesthesia.

What makes this study particularly valuable is its focus on two specific patient groups that face higher risks during surgery. The first sub-group includes up to 25 patients who may be experiencing right ventricular failure, where the right side of the heart struggles to pump blood effectively. The second sub-group includes up to 50 patients aged 45 or older who are undergoing heart surgery with cardiopulmonary bypass and are at increased risk for cerebrovascular problems. By studying these specific populations, researchers hope to develop better monitoring techniques that could ultimately improve surgical outcomes for high-risk patients.

Patients interested in participating must be at least 18 years old, scheduled for appropriate surgery, and able to provide informed consent. The study excludes pregnant women and patients participating in other conflicting research studies. Each sub-group has additional specific criteria to ensure patient safety and appropriate data collection. The monitoring period will last up to 72 hours during surgery and the immediate recovery period in the intensive care unit.

This type of clinical research is incredibly important for advancing patient care in surgical settings. Hemodynamic monitoring technology has revolutionized how doctors manage critically ill patients during complex procedures. By continuously tracking blood pressure, heart function, and oxygen delivery to organs, medical teams can make immediate adjustments to anesthesia, fluids, and medications to maintain stability. Studies like this one help refine these technologies and develop new approaches that could benefit countless future patients.

For patients and families facing major surgery, understanding that researchers are continually working to improve monitoring and safety can provide reassurance. Clinical trials represent the forefront of medical innovation, where new devices and techniques are carefully evaluated before becoming standard practice. Participation in such studies contributes valuable knowledge that helps the medical community develop better ways to protect patients during high-risk procedures. The data collected from this study will specifically help Edwards Lifesciences further develop their monitoring platform to better serve patients needing complex surgical care.

Patients considering participation should discuss the study thoroughly with their healthcare team and the research coordinators, including Cristina Johnson, the central contact for the trial. Understanding the commitment involved, potential benefits, and any risks is essential before making a decision about joining medical research. While the study involves additional monitoring beyond standard care, it does not change the surgical procedure itself and aims to gather information that could improve future patient outcomes across many healthcare institutions.